Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205299 | 1.00 | ACE (0.54) | ACEMEN1KMT2AMAPK1NAMPT | |
| SCHEMBL30626775 | 1.00 | ACE (0.54) | ACEMEN1KMT2AMAPK1NAMPT | |
| SCHEMBL31038337 | 1.00 | ACE (0.54) | ACEMEN1KMT2AMAPK1NAMPT | |
| SCHEMBL6482316 | 1.00 | ACE (0.54) | ACEMEN1KMT2AMAPK1NAMPT | |
| SCHEMBL27393607 | 0.89 | MEN1 (0.45) | ACEMEN1KMT2AMAPK1NAMPT | |
| SCHEMBL30944609 | 0.89 | MEN1 (0.45) | ACEMEN1KMT2AMAPK1NAMPT | |
| SCHEMBL6251794 | 0.88 | MEN1 (0.44) | ACEMEN1KMT2AMAPK1NAMPT | |
| SCHEMBL25960274 | 0.88 | MEN1 (0.44) | ACEMEN1KMT2AMAPK1NAMPT | |
| SCHEMBL18066415 | 0.86 | ACE (0.56) | ACEUCHL1GPR119 | |
| SCHEMBL14744581 | 0.86 | ACE (0.56) | ACEUCHL1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1558253-A4 | PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050250814-A1 | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-11-10 | — | — | US | disclosed |
| EP-1370558-B1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1368340-B1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-1558253-A2 | PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | GUILFORD PHARMACEUTICALS | 2005-03-31 | — | — | US | disclosed |
| WO-2004042351-A2 | PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-04-29 | — | — | US | disclosed |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | ACE 2426/4885MEN1 683/4885KMT2A 2707/4885 |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | MC1R, MC4R, MC5R | ACE 2963/4885MEN1 1304/4885KMT2A 2353/4885 |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | MC1R, MC4R, MC5R | ACE 3090/4885MEN1 1206/4885KMT2A 2374/4885 |
| US-20050250814-A1 | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity | CCR2, CCR1, CCRL2 | ACE 1992/4885MEN1 4327/4885KMT2A 1675/4885 |
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | DPP4, DPP3, DPP7 | ACE 20/4885MEN1 3669/4885KMT2A 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.